Genes differentially expressed in secretory versus proliferative endometrium

Abstract

The present invention compares expression profiles from matched samples to identify differential gene expression. Samples are matched according to physiological, pharmacological and/or disease state. Comparison of matched samples eliminates gene expression differences that are the result of changes in variables that are not of interest. The gene expression differences that remain can be attributed with a high degree of confidence to the unmatched variation. The gene expression differences thus identified can be used for example to diagnose disease, identify physiological state, design drugs, and monitor therapies.

1 - 9 . (canceled)  
     
     
         10 . A method of diagnosing endometrial adenocarcinoma in a first endometrial sample comprising: 
 measuring the gene expression in the first endometrial sample of each of the following genes: MIF, cyclin A1, MRG1, HOX1, Alpha 2 collagen type VI, Adducin, Cyclin B and PKC zeta, to obtain a gene expression measurement for each of said genes in the first endometrial sample;    comparing the gene expression measurement of each of said genes in the first endometrial sample to a gene expression measurement of the same gene in a second endometrial sample from normal endometrium; and    identifying the first endometrial sample as being endometrial adenocarcinoma if MIF, cyclin A1, cyclin B1 and PKC zeta are expressed at a higher level in the first endometrial sample than in the second endometrial sample and MRG1, HOX1, Alpha 2 collagen type VI and Adducin are expressed at a lower level in the first endometrial sample than in the second endometrial sample.